Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Cenobamate in Severe Hepatic Impairment
NCT04791553Phase 1Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Jun 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of cenobamate in focal onset seizure (2 arms), sponsored by SK Life Science, Inc. Primary endpoints: Maximum Observed Plasma Concentration at 40 days, Area Under the Concentration-Time Curve to Last Measurable Concentration at 40 days and 1 more. Started Jun 2021; status: completed.
02
Drugs
cenobamate
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT04791553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04791553.